|
시장보고서
상품코드
1651002
세계의 심부전 치료제 시장Heart Failure Drugs |
||||||
심부전 치료제 세계 시장, 2030년까지 191억 달러에 달할 전망
2024년 95억 달러로 추정되는 심부전 치료제 세계 시장은 2030년에는 191억 달러에 달할 것으로 예상되며, 분석 기간인 2024-2030년 CAGR 12.4%로 성장할 것으로 예측됩니다.
미국 시장 24억 달러, 중국은 CAGR 16.3%로 성장 전망
미국의 심부전 치료제 시장은 2024년 24억 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 46억 달러의 시장 규모에 도달할 것으로 예상되며, 2024-2030년 분석 기간 동안 16.3%의 CAGR을 기록할 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 8.6% 및 10.2%의 CAGR을 기록할 것으로 예측됩니다. 유럽에서는 독일이 약 9.6%의 CAGR로 성장할 것으로 예상됩니다.
세계 심부전 치료제 시장 - 주요 동향 및 촉진요인 정리
심부전 치료제가 이 광범위한 증상 관리에 중요한 이유는 무엇일까?
심부전 치료제는 전 세계 수백만 명이 앓고 있는 심부전을 관리하는 데 있어 매우 중요한 역할을 하고 있으며, 증상 완화, 삶의 질 개선, 생존기간 연장에 도움을 주고 있습니다. 심부전은 심장이 혈액을 내보내는 능력이 저하된 만성질환으로, 효과적으로 관리하지 않으면 심각한 이환율과 사망률을 초래할 수 있습니다. 심부전 치료제의 주요 목표는 심장의 부담을 줄이고 혈류를 개선하며 병의 악화를 막는 것. 베타차단제, 안지오텐신 전환효소(ACE) 억제제, 이뇨제 등의 약물은 혈압을 낮추고 심장의 리듬을 조절하며 혈액순환 장애로 인해 축적되기 쉬운 과도한 수분을 배출하여 심부전을 관리하기 위해 일반적으로 처방됩니다. 관리하기 위해 일반적으로 처방됩니다. 이러한 약물이 없으면 환자는 체액 저류, 피로, 호흡곤란과 같은 합병증 위험이 높아집니다. 심부전이 심해지면 입원이나 돌연사로 이어질 수 있습니다. 따라서 심부전 치료제의 개발과 최적화는 증상 조절뿐만 아니라 입원을 줄이고 장기적인 생존 예후를 개선하는 데에도 필수적입니다.
심부전 치료제의 종류에 따라 환자 예후가 어떻게 달라질 수 있을까?
심부전 치료의 중심이 되는 약물에는 여러 종류가 있으며, 각각 질병의 다른 측면을 다루며, ACE 억제제와 안지오텐신 II 수용체 길항제(ARB)는 종종 일차 선택 약물이기도 합니다. 베타차단제는 혈관을 이완시키고 심장의 부담을 줄여 혈압을 낮추고 혈류를 개선하며, 심박수를 낮추고 수축력을 감소시켜 심장이 더 효율적으로 작동하고 시간이 지남에 따라 부담을 회복할 수 있도록 도와주는 필수적인 약물군입니다. 일반적으로 이뇨제로 알려진 이뇨제는 과도한 수분을 체외로 배출하여 부종을 개선하고 폐에 축적되는 수분을 감소시켜 호흡을 개선합니다. 또한, 안지오텐신 수용체-네프릴라이신 억제제(ARNI)와 같은 새로운 계열의 약물은 심장의 부담을 줄이고 증상의 악화를 방지하여 심장 기능을 개선하는 데 매우 효과적인 것으로 밝혀졌습니다. 사쿠비트릴/바르살탄과 같은 약물은 임상시험에서 생존율의 유의미한 개선과 입원율 감소를 보여주었습니다. 또 다른 중요한 계열은 알도스테론 길항제로, 과도한 알도스테론의 유해한 작용을 억제하는 약제입니다. 이 호르몬은 체액 저류를 촉진하고 심장 기능을 악화시켜 심부전을 악화시킵니다. 심부전에 관여하는 다양한 경로를 표적으로 삼음으로써 이러한 약물은 시너지 효과를 발휘하여 증상을 완화하고 질병의 진행을 늦추며 환자의 전반적인 결과를 개선합니다.
심부전 치료제의 최신 개발 및 혁신은 무엇인가?
심부전 치료 환경은 진화하고 있으며, 더 나은 관리와 결과에 대한 희망을 주는 몇 가지 유망한 개발이 있습니다. 최근 몇 년 동안 가장 중요한 혁신 중 하나는 나트륨 포도당 공수송체 2(SGLT2) 억제제의 사용입니다. 처음에는 제2형 당뇨병 치료제로 개발되었지만, 다파글리플로진이나 엠파글리플로진과 같은 이 약제들은 당뇨병이 없는 심부전 환자에서도 입원 및 사망 위험을 감소시키는 놀라운 결과를 보여주었습니다. 이 계열의 약물은 신장이 과도한 포도당과 나트륨을 제거하도록 도와 혈액량과 혈압을 낮춰 심장에 부담을 덜어주는 역할을 합니다. 또한, 유전자 치료는 미래의 심부전 치료의 가능성으로 주목받고 있습니다. 연구자들은 특정 유전자를 수정하여 손상된 심장 조직을 복구하고 재생하여 증상 치료가 아닌 장기적인 해결책을 제공하는 방법을 모색하고 있습니다. 건강한 심장 조직의 재생을 촉진하여 심장 손상을 복구할 수 있는 새로운 생물학적 제제 및 세포 기반 치료법을 개발하는 것도 혁신적인 분야입니다. 이러한 첨단 치료법의 효능을 검증하기 위한 임상시험이 진행 중이며, 향후 수십 년 동안 심부전 치료에 있어 큰 돌파구가 될 수 있습니다. 이러한 개발은 기존 약물의 지속적인 개선과 함께 심부전 치료 전략을 지속적으로 개선하여 환자들에게 보다 개인화되고 효과적인 치료 옵션을 제공하고 있습니다.
심부전 치료제 시장의 주요 성장 촉진요인은?
심부전 치료제 시장의 성장은 의학의 발전, 인구통계학적 변화, 환자 니즈의 변화와 직접적으로 관련된 몇 가지 요인에 의해 이루어집니다. 가장 중요한 요인 중 하나는 인구의 고령화와 심부전의 주요 위험요인인 고혈압, 당뇨병, 관상동맥질환 등 심혈관질환의 유병률 증가로 인해 심부전 유병률이 상승하고 있다는 점입니다. 세계 인구의 고령화와 만성질환의 확산에 따라 효과적인 심부전 치료제에 대한 수요는 지속적으로 증가하고 있습니다. 또한, 신약개발과 제약기술의 발전으로 SGLT2 억제제나 ARNI와 같은 보다 효과적인 신약이 개발되어 표준치료에 변화를 가져왔고, 심부전 치료제 시장도 확대되고 있습니다. 또한, 특히 진행성 심부전 환자의 삶의 질 향상에 대한 관심이 높아지고 있으며, 새로운 약물 요법은 병원 재입원을 줄이고 증상을 보다 효과적으로 관리하는 것을 목표로 하고 있습니다. 또 다른 중요한 원동력은 더 나은 진단 도구와 스크리닝 프로그램에 의해 촉진되는 심부전 인식과 조기 진단의 증가로 조기 개입과 더 지속적인 약물 사용으로 이어집니다. 또한, 제약 업계에서는 유전적 요인, 임상적 요인, 생활습관 요인에 따라 환자 개개인에게 맞춤화된 치료를 제공하는 맞춤형 의료로의 전환도 시장을 확대시키고 있습니다. 이러한 개별화 접근법은 심부전을 보다 효과적으로 관리할 수 있게 해주고, 혁신적인 표적 치료제에 대한 수요를 더욱 증가시키고 있습니다. 마지막으로, 공공 및 민간 부문의 연구개발에 대한 막대한 투자는 새로운 치료법의 지속적인 파이프라인을 보장하고, 보다 효과적인 새로운 솔루션이 시장에 출시됨에 따라 심부전 치료제 시장의 성장을 촉진할 것입니다.
부문
부문(심부전 치료제)
조사 대상 기업 사례(총 11건)
- AstraZeneca PLC
- Bayer AG
- Boehringer Ingelheim(Canada) Ltd.
- Bristol-Myers Squibb Company
- CRC Health
- Exelixis, Inc.
- GlaxoSmithKline plc
- Johnson & Johnson
- Lunan Pharmaceuticals Co. Ltd.
- Merck & Co., Inc.
- Mylan N.V.
- Novartis AG
- Pfizer, Inc.
- Sanofi S.A.
- Shanghai Haini Pharmaceutical Co., Ltd.
- Shanghai Xudong Haipu Pharmaceutical Co., Ltd.
- The National Council for Palliative Care
- Valeant Pharmaceuticals International, Inc.
목차
제1장 조사 방법
제2장 주요 요약
- 시장 개요
- 주요 기업
- 시장 동향과 성장 촉진요인
- 세계 시장 전망
제3장 시장 분석
- 미국
- 캐나다
- 일본
- 중국
- 유럽
- 프랑스
- 독일
- 이탈리아
- 영국
- 스페인
- 러시아
- 기타 유럽
- 아시아태평양
- 호주
- 인도
- 한국
- 기타 아시아태평양
- 라틴아메리카
- 아르헨티나
- 브라질
- 멕시코
- 기타 라틴아메리카
- 중동
- 이란
- 이스라엘
- 사우디아라비아
- 아랍에미리트
- 기타 중동
- 아프리카
제4장 경쟁
ksm 25.02.21Global Heart Failure Drugs Market to Reach US$19.1 Billion by 2030
The global market for Heart Failure Drugs estimated at US$9.5 Billion in the year 2024, is expected to reach US$19.1 Billion by 2030, growing at a CAGR of 12.4% over the analysis period 2024-2030.
The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 16.3% CAGR
The Heart Failure Drugs market in the U.S. is estimated at US$2.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.6 Billion by the year 2030 trailing a CAGR of 16.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.6% and 10.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.6% CAGR.
Global Heart Failure Drugs Market - Key Trends and Drivers Summarized
Why Are Heart Failure Drugs Critical in Managing This Widespread Condition?
Heart failure drugs play a pivotal role in managing a condition that affects millions worldwide, helping to reduce symptoms, improve quality of life, and prolong survival. Heart failure, a chronic condition where the heart’s ability to pump blood is compromised, can lead to significant morbidity and mortality if not effectively managed. The primary goal of heart failure drugs is to alleviate the strain on the heart, improve blood flow, and prevent the worsening of the condition. Medications such as beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and diuretics are commonly prescribed to manage heart failure by reducing blood pressure, regulating heart rhythms, and eliminating excess fluids that can build up due to poor circulation. Without these medications, patients face a higher risk of complications such as fluid retention, fatigue, and shortness of breath. In severe cases, unmanaged heart failure can result in hospitalizations or even sudden death. Therefore, the development and optimization of heart failure drugs are essential not only for symptom control but also for reducing hospital admissions and improving long-term survival outcomes.
How Do Different Classes of Heart Failure Drugs Work to Improve Patient Outcomes?
There are several classes of drugs that are central to heart failure management, each addressing different aspects of the disease. ACE inhibitors and angiotensin II receptor blockers (ARBs) are often first-line therapies. They work by relaxing blood vessels and reducing the workload on the heart, which lowers blood pressure and improves blood flow. Beta-blockers are another essential class of drugs that reduce heart rate and decrease the force of contraction, allowing the heart to work more efficiently and recover from strain over time. For patients who retain excess fluids, diuretics, commonly known as water pills, help to remove this excess fluid from the body, reducing swelling and improving breathing by lowering fluid buildup in the lungs. Additionally, newer drug classes like angiotensin receptor-neprilysin inhibitors (ARNIs) have emerged as highly effective in improving heart function by reducing strain on the heart and preventing worsening of symptoms. These drugs, like sacubitril/valsartan, have shown significant improvements in survival rates and reduced hospitalizations in clinical trials. Another important class includes aldosterone antagonists, which block the harmful effects of excess aldosterone—a hormone that can exacerbate heart failure by promoting fluid retention and worsening cardiac function. By targeting different pathways involved in heart failure, these medications work synergistically to reduce symptoms, slow disease progression, and improve overall outcomes for patients.
What Are the Latest Developments and Innovations in Heart Failure Drug Therapies?
The landscape of heart failure treatment is evolving, with several promising developments that offer hope for better management and outcomes. One of the most significant innovations in recent years is the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors. Initially developed as a treatment for type 2 diabetes, these drugs, such as dapagliflozin and empagliflozin, have demonstrated impressive results in reducing the risk of hospitalization and death in heart failure patients, even those without diabetes. This class of drugs works by helping the kidneys remove excess glucose and sodium, which in turn reduces blood volume and pressure, easing the burden on the heart. Additionally, gene therapy is gaining attention as a potential future treatment for heart failure. Researchers are exploring how modifying certain genes could repair or regenerate damaged heart tissue, offering a long-term solution rather than just symptom management. Another exciting area of innovation is the development of novel biologics and cell-based therapies that could potentially reverse heart damage by promoting the regeneration of healthy heart tissue. Clinical trials are ongoing to test the efficacy of these advanced therapies, which could represent a significant breakthrough in how heart failure is treated in the coming decades. These developments, along with ongoing improvements in existing drug formulations, are continuously refining heart failure treatment strategies, offering patients more personalized and effective options.
What Are the Key Growth Drivers in the Heart Failure Drugs Market?
The growth in the heart failure drugs market is driven by several factors directly related to advancements in medical science, shifting demographics, and changing patient needs. One of the most significant factors is the rising prevalence of heart failure, driven by an aging population and the increasing incidence of cardiovascular diseases such as hypertension, diabetes, and coronary artery disease, which are major risk factors for heart failure. As the global population ages and chronic conditions become more prevalent, the demand for effective heart failure treatments continues to rise. In addition, advances in drug discovery and pharmaceutical technology have led to the development of new, more effective medications like SGLT2 inhibitors and ARNIs, which are transforming the standard of care and expanding the market for heart failure drugs. Furthermore, there is a growing focus on improving quality of life for heart failure patients, particularly in advanced cases, where new drug therapies aim to reduce hospital readmissions and manage symptoms more effectively. Another key driver is the increasing awareness and early diagnosis of heart failure, facilitated by better diagnostic tools and screening programs, leading to earlier intervention and more sustained use of medications. Moreover, the pharmaceutical industry’s shift toward personalized medicine, where treatments are tailored to the individual patient based on genetic, clinical, and lifestyle factors, is also expanding the market. These personalized approaches enable more effective management of heart failure, further driving demand for innovative and targeted therapies. Finally, the significant investment in research and development by both public and private sectors ensures a continuous pipeline of new treatments, fueling the growth of the heart failure drugs market as new, more effective solutions are brought to market.
SCOPE OF STUDY:
The report analyzes the Heart Failure Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Segment (Heart Failure Drugs)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 11 Featured) -
- AstraZeneca PLC
- Bayer AG
- Boehringer Ingelheim (Canada) Ltd.
- Bristol-Myers Squibb Company
- CRC Health
- Exelixis, Inc.
- GlaxoSmithKline plc
- Johnson & Johnson
- Lunan Pharmaceuticals Co. Ltd.
- Merck & Co., Inc.
- Mylan N.V.
- Novartis AG
- Pfizer, Inc.
- Sanofi S.A.
- Shanghai Haini Pharmaceutical Co., Ltd.
- Shanghai Xudong Haipu Pharmaceutical Co., Ltd.
- The National Council for Palliative Care
- Valeant Pharmaceuticals International, Inc.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Global Economic Update
- Heart Failure Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Prevalence of Cardiovascular Diseases Propels Growth of the Heart Failure Drugs Market
- Increasing Aging Population Expands Demand for Effective Heart Failure Treatments
- Advancements in Drug Delivery Systems Spur Innovation in Heart Failure Drug Formulations
- Growing Focus on Personalized Medicine Strengthens the Business Case for Targeted Heart Failure Therapies
- Development of Novel Drug Classes Such as SGLT2 Inhibitors Drives Market Expansion
- Rising Healthcare Expenditure and Access to Advanced Treatments Generate Opportunities in Emerging Markets
- Increasing Adoption of Combination Therapies Strengthens Market Growth for Heart Failure Drugs
- Surge in Demand for Oral Drugs and Non-Invasive Treatments Expands the Addressable Market
- Growing Focus on Reducing Hospital Readmissions Drives the Need for Effective Long-Term Heart Failure Therapies
- Expanding Use of Biomarkers for Disease Monitoring Enhances Adoption of Tailored Drug Regimens
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Heart Failure Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Heart Failure Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Heart Failure Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 4: World 15-Year Perspective for Heart Failure Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 5: USA Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 6: USA Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- CANADA
- TABLE 7: Canada Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 8: Canada Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- JAPAN
- Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 9: Japan Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 10: Japan Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- CHINA
- Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 11: China Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 12: China Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- EUROPE
- Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 13: Europe Recent Past, Current & Future Analysis for Heart Failure Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 14: Europe Historic Review for Heart Failure Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 15: Europe 15-Year Perspective for Heart Failure Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
- FRANCE
- Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 16: France Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 17: France Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- GERMANY
- Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 18: Germany Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 19: Germany Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- ITALY
- TABLE 20: Italy Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 21: Italy Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- UNITED KINGDOM
- Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 22: UK Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 23: UK Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- SPAIN
- TABLE 24: Spain Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 25: Spain Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- RUSSIA
- TABLE 26: Russia Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 27: Russia Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- REST OF EUROPE
- TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 29: Rest of Europe Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- ASIA-PACIFIC
- Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for Heart Failure Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 31: Asia-Pacific Historic Review for Heart Failure Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 32: Asia-Pacific 15-Year Perspective for Heart Failure Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
- AUSTRALIA
- Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 33: Australia Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 34: Australia Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- INDIA
- Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 35: India Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: India Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- SOUTH KOREA
- TABLE 37: South Korea Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 38: South Korea Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- REST OF ASIA-PACIFIC
- TABLE 39: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 40: Rest of Asia-Pacific Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- LATIN AMERICA
- Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 41: Latin America Recent Past, Current & Future Analysis for Heart Failure Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 42: Latin America Historic Review for Heart Failure Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 43: Latin America 15-Year Perspective for Heart Failure Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
- ARGENTINA
- TABLE 44: Argentina Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: Argentina Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- BRAZIL
- TABLE 46: Brazil Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 47: Brazil Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- MEXICO
- TABLE 48: Mexico Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 49: Mexico Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- REST OF LATIN AMERICA
- TABLE 50: Rest of Latin America Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: Rest of Latin America Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- MIDDLE EAST
- Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 52: Middle East Recent Past, Current & Future Analysis for Heart Failure Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 53: Middle East Historic Review for Heart Failure Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 54: Middle East 15-Year Perspective for Heart Failure Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
- IRAN
- TABLE 55: Iran Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 56: Iran Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- ISRAEL
- TABLE 57: Israel Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 58: Israel Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- SAUDI ARABIA
- TABLE 59: Saudi Arabia Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: Saudi Arabia Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- UNITED ARAB EMIRATES
- TABLE 61: UAE Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 62: UAE Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- REST OF MIDDLE EAST
- TABLE 63: Rest of Middle East Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 64: Rest of Middle East Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- AFRICA
- Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 65: Africa Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: Africa Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
